ADC Therapeutics(US:ADCT) Newsfilter·2024-05-06 10:00Core Insights - Initial data from a Phase 2 clinical trial of ZYNLONTA® in patients with relapsed/refractory marginal zone lymphoma (MZL) shows promising results, with 13 out of 15 patients achieving a complete response [1][2][3] - The trial is being conducted at the Sylvester Comprehensive Cancer Center and is led by Dr. Izidore Lossos, focusing on the safety and efficacy of ZYNLONTA over six cycles [2][3] - ZYNLONTA was well-tolerated, with safety profiles consistent with previous data, and only two patients discontinued due to toxicity [3] Study Details - The study is a single-arm, open-label trial involving 50 patients, evaluating ZYNLONTA's effectiveness over 18 weeks in patients previously treated with at least one line of systemic therapy [2] - As of March 30, 2024, 15 patients were evaluable, with 13 achieving a complete response and one a partial response, all maintaining their responses at the data cutoff [2][3] Market Opportunity - There is a significant unmet medical need for relapsed/refractory MZL, with approximately 3,000 to 4,000 patients treated annually in the U.S. [4] - The company plans to expand the number of trial sites to accelerate enrollment, with potential regulatory pathways being considered if results remain positive [4] Product Information - ZYNLONTA is a CD19-directed antibody drug conjugate that targets CD19-expressing cells, leading to tumor cell death [5] - It has received accelerated approval from the FDA and conditional approval from the European Medicines Agency for treating relapsed or refractory large B-cell lymphoma after two or more lines of therapy [5][6] Company Overview - ADC Therapeutics is a leader in antibody drug conjugates, focusing on transforming treatment paradigms for hematologic malignancies and solid tumors [8] - The company is based in Lausanne, Switzerland, with operations in London and New Jersey, and is advancing multiple ADCs in clinical and preclinical development [8][9]